THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER JOINS PHASE III TRIAL FOR METASTATIC MELANOMA
NEW YORK, April 9 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute has joined Delcath's Phase III clinical trial for the treatment of metastatic melanoma in the liver. Ohio State is the twelfth center to join this multi-center trial testing the Company's Percutaneous Hepatic Perfusion (PHP(TM)) System for the isolated, high-dose delivery of the anti-cancer agent melphalan.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )
Delcath and Ohio State have entered into a clinical research agreement to conduct the Phase III National Cancer Institute (NCI) led study. Dr. Mark Bloomston, a surgical oncologist specializing in regional cancer therapy, will serve as the Principal Investigator. Commenting on joining this trial, Dr. Bloomston stated, "The Delcath PHP System(TM) is a welcome addition to the currently available therapies for liver cancer, and we look forward to treating patients in this trial. Metastatic melanoma, once it reaches the liver, has few viable treatment options. This technology offers a very promising approach for targeting the disease in the liver and we are eager to provide this modality to our patients."
Commenting on this twelfth center joining the trial, Richard L. Taney, President and CEO of Delcath, stated, "We are delighted to have Ohio State and Dr. Bloomston join this trial as we continue to expand to an increasing number of leading cancer centers in the United States. The prestige of these centers is a validation of the need for a viable treatment option for these very ill patients. Continuing to expand this trial assists in the acceleration of enrollment, increases the awareness of the Delcath PHP System(TM) among physicians, and expands patient access to PHP(TM)."
About The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute is one of only 40 NCI-designated Comprehensive Cancer Centers in the United States and the only freestanding cancer hospital in the Midwest. Ranked among the top 20 cancer hospitals in the nation, The James is the 172-bed adult patient-care component of the cancer program at The Ohio State University. For more information, visit www.jamesline.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Related medicine technology :1
. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors2
. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center3
. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited4
. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center5
. Vantia Therapeutics Pipeline Continues to Mature6
. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival7
. ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations8
. AlphaVax Continues to Expand the Use of Its Vaccine Platform9
. Replidyne Discontinues Phase III Trial10
. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months11
. Medarex Announces Ipilimumab Program Continues to Move Forward